MEI Pharma (MEIP) Competitors $3.19 +0.41 (+14.71%) Closing price 09/10/2025Extended Trading$3.19 0.00 (0.00%) As of 09/10/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MEIP vs. AUTL, ETHZ, ATXS, ADCT, PRTC, FDMT, YMAB, EOLS, KMDA, and AURAShould you be buying MEI Pharma stock or one of its competitors? The main competitors of MEI Pharma include Autolus Therapeutics (AUTL), Flag Ship Acquisition (ETHZ), Astria Therapeutics (ATXS), ADC Therapeutics (ADCT), PureTech Health (PRTC), 4D Molecular Therapeutics (FDMT), Y-mAbs Therapeutics (YMAB), Evolus (EOLS), Kamada (KMDA), and Aura Biosciences (AURA). These companies are all part of the "pharmaceutical products" industry. MEI Pharma vs. Its Competitors Autolus Therapeutics Flag Ship Acquisition Astria Therapeutics ADC Therapeutics PureTech Health 4D Molecular Therapeutics Y-mAbs Therapeutics Evolus Kamada Aura Biosciences MEI Pharma (NASDAQ:MEIP) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability. Do institutionals and insiders believe in MEIP or AUTL? 52.4% of MEI Pharma shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 3.1% of MEI Pharma shares are held by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, MEIP or AUTL? MEI Pharma has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500. Is MEIP or AUTL more profitable? Autolus Therapeutics' return on equity of -56.18% beat MEI Pharma's return on equity.Company Net Margins Return on Equity Return on Assets MEI PharmaN/A -77.00% -64.79% Autolus Therapeutics N/A -56.18%-29.61% Which has preferable earnings and valuation, MEIP or AUTL? MEI Pharma has higher earnings, but lower revenue than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than MEI Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMEI PharmaN/AN/A$17.78M-$4.75-0.67Autolus Therapeutics$10.12M46.29-$220.66M-$0.84-2.10 Do analysts rate MEIP or AUTL? Autolus Therapeutics has a consensus target price of $9.12, suggesting a potential upside of 418.18%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Autolus Therapeutics is more favorable than MEI Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MEI Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Autolus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Does the media refer more to MEIP or AUTL? In the previous week, Autolus Therapeutics had 2 more articles in the media than MEI Pharma. MarketBeat recorded 2 mentions for Autolus Therapeutics and 0 mentions for MEI Pharma. Autolus Therapeutics' average media sentiment score of 1.02 beat MEI Pharma's score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment MEI Pharma Neutral Autolus Therapeutics Positive SummaryAutolus Therapeutics beats MEI Pharma on 12 of the 14 factors compared between the two stocks. Get MEI Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MEIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MEIP vs. The Competition Export to ExcelMetricMEI PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$104.72M$2.64B$6.10B$10.55BDividend YieldN/A56.71%5.69%4.75%P/E Ratio-0.6723.6985.4727.60Price / SalesN/A556.27582.22224.03Price / Cash0.51173.2337.9261.55Price / Book0.645.5313.136.76Net Income$17.78M$32.78M$3.30B$275.88M7 Day PerformanceN/A5.82%4.29%2.81%1 Month Performance14.71%13.16%9.45%9.24%1 Year Performance18.99%1.69%86.64%35.42% MEI Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MEIPMEI Pharma1.0138 of 5 stars$3.19+14.7%N/A+17.7%$104.72MN/A-0.67100Gap UpHigh Trading VolumeAUTLAutolus Therapeutics3.5337 of 5 stars$1.59+1.9%$9.12+473.6%-56.7%$415.18M$10.12M-1.89330Positive NewsAnalyst ForecastETHZFlag Ship AcquisitionN/A$2.48-1.2%N/AN/A$412.72MN/A-0.167News CoverageAnalyst ForecastATXSAstria Therapeutics2.6039 of 5 stars$7.36+0.8%$30.20+310.3%-25.1%$411.98MN/A-3.6630News CoveragePositive NewsAnalyst ForecastADCTADC Therapeutics2.8633 of 5 stars$4.02+10.0%$7.75+93.0%+47.9%$410.62M$70.84M-2.56310Analyst ForecastAnalyst RevisionPRTCPureTech Health0.0742 of 5 stars$18.15+7.4%N/A-6.6%$408.45M$4.83M0.00100Positive NewsAnalyst ForecastGap UpFDMT4D Molecular Therapeutics2.4364 of 5 stars$8.35-0.5%$30.40+264.1%+3.0%$391.83M$40K-2.37120Analyst ForecastYMABY-mAbs Therapeutics1.7173 of 5 stars$8.61flat$9.62+11.8%N/A$391.24M$87.68M-17.22150EOLSEvolus3.9663 of 5 stars$6.14+2.5%$21.25+246.1%-62.4%$387.47M$266.27M-6.27170KMDAKamada4.5336 of 5 stars$6.87+3.0%$13.00+89.2%+30.0%$383.56M$160.95M20.21360Positive NewsAnalyst ForecastAnalyst RevisionAURAAura Biosciences2.1978 of 5 stars$6.17+0.2%$22.00+256.6%-27.9%$382.66MN/A-3.1550News CoverageAnalyst Forecast Related Companies and Tools Related Companies Autolus Therapeutics Alternatives Flag Ship Acquisition Alternatives Astria Therapeutics Alternatives ADC Therapeutics Alternatives PureTech Health Alternatives 4D Molecular Therapeutics Alternatives Y-mAbs Therapeutics Alternatives Evolus Alternatives Kamada Alternatives Aura Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MEIP) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MEI Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MEI Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
